Fourchette de valorisation composite · prudent ¥2,450–¥2,650 / raisonnable ¥3,250–¥4,150 / optimiste ¥5,150–¥5,450. À ¥3,436, Dans la fourchette de valeur intrinsèque raisonnable.
FUJIFILM Cellular Dynamics opened a new Madison iPSC headquarters and manufacturing facility, part of a $200 million U.S. investment.
Possible impact:May affect expectations for cell therapy manufacturing and life-sciences growth.
Fujifilm reported record FY2026 revenue, operating income and net income, and guided for further growth in FY2027.
Possible impact:May affect expectations for sustained growth in healthcare, semiconductor materials and imaging.
FUJIFILM Toyama Chemical received Japanese approval for SAVYSCUS Injection, a regenerative medical product for meniscal injury.
Possible impact:May affect expectations for regenerative medicine commercialization and healthcare differentiation.
Fujifilm developed a fluorine-free negative ArF immersion photoresist for advanced AI semiconductor nodes and began sampling.
Possible impact:May affect expectations for semiconductor materials competitiveness and PFAS-replacement demand.
Fujifilm invested in Austria’s VALANX Biotech to strengthen ADC CDMO technology and manufacturing capabilities.
Possible impact:May affect expectations for Bio CDMO positioning in the fast-growing ADC market.
Automatically summarized from public sources; for context only, not investment advice.
Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.
FUJIFILM Holdings Corporation provides products and services in the fields of healthcare, electronics, business innovation, and imaging in Japan, the Americas, Europe, Asia, and internationally. The Healthcare segment offers products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment; equipment and materials for medical systems; drug discovery support, such as iPS cells; and cell culture media and reagents. Its Electronic segment provides display and touch panel, semiconductor and image sensors, and functional film materials; storage media and archiving services; semiconductor and display materials; industrial equipment; and fine chemicals. The Business Innovation segment offers office equipment, including multi-function devices and printers; problem-solving document services tailored to diverse business formats and roles, including system integration, cloud service, business process outsourcing, and others; equipment and materials for graphic communications; and inks and industrial inkjet printheads. Its Imaging segment provides color films, instant cameras, developing and printing systems, color papers, and photo printing services; TV and cinema lenses, surveillance cameras, industrial lenses for production line inspection, and projectors; instant photo systems; services for photofinishing; digital cameras; and optical devices. FUJIFILM Holdings Corporation was incorporated in 1934 and is headquartered in Minato, Japan.
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
Pas encore d'analyse sur cette valeur dans votre langue.
